Advertisement
YOU ARE HERE: LAT HomeCollectionsSciclone Pharmaceuticals
IN THE NEWS

Sciclone Pharmaceuticals

FEATURED ARTICLES
BUSINESS
May 20, 1994 | From Times Staff and Wire Reports
SciClone Reports on Hepatitis Drug: SciClone Pharmaceuticals said ongoing clinical trials of its treatment for chronic hepatitis B in Taiwan have not shown indications of drug toxicity or adverse reactions. However, the company warned against concluding that thymosin alpha 1 has been proven effective in treating Asian patients, because the results were based on a small number of patients in the early stages of testing. The stock of the San Mateo, Calif.
ARTICLES BY DATE
BUSINESS
May 20, 1994 | From Times Staff and Wire Reports
SciClone Reports on Hepatitis Drug: SciClone Pharmaceuticals said ongoing clinical trials of its treatment for chronic hepatitis B in Taiwan have not shown indications of drug toxicity or adverse reactions. However, the company warned against concluding that thymosin alpha 1 has been proven effective in treating Asian patients, because the results were based on a small number of patients in the early stages of testing. The stock of the San Mateo, Calif.
Advertisement
BUSINESS
April 27, 1993
California-based firms ranked by dollar amount of offering. Offering Rank Company ($ millions) 1 Foodmaker 180.0 2 Dames & Moore 115.0 3 Pref. Income Opportunity 108.8 4 Ventritex 84.6 5 Gilead Sciences 75.0 6 Providential 67.2 7 North American Mortgage 63.3 8 Pyxis Corporation 56.0 9 Protein Design Labs 52.5 10 Matrix Pharmaceutical 52.5 11 Callaway Golf 52.0 12 PeopleSoft 51.0 13 Trident Microsystems 51.0 14 Cheesecake Factory 46.7 15 Media Vision Technology 45.0 16 Amylin Pharmaceuticals 44.
BUSINESS
May 16, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Without a product to market or its first dollar in sales, the small Silicon Valley biotechnology company counted on the allure of a promising experimental drug to entice investors. It was not disappointed. Buoyed by predictions of a drug with billion-dollar sales potential, investors drove up the company's stock market value to among the highest in biotech. Then the bubble burst for SciClone Pharmaceuticals.
BUSINESS
May 16, 1994 | DAVID R. OLMOS, TIMES STAFF WRITER
Without a product to market or its first dollar in sales, the small Silicon Valley biotechnology company counted on the allure of a promising experimental drug to entice investors. It was not disappointed. Buoyed by predictions of a drug with billion-dollar sales potential, investors drove up the company's stock market value to among the highest in biotech. Then the bubble burst for SciClone Pharmaceuticals.
BUSINESS
April 11, 1997 | BARBARA MARSH, TIMES STAFF WRITER
In what is believed to be the first case alleging insider trading by clinical researchers, federal regulators have accused several physicians and others of trading on insider information from researchers involved in developing an experimental drug to treat the liver ailment hepatitis B.
BUSINESS
April 11, 1997 | BARBARA MARSH, TIMES STAFF WRITER
Federal regulators have accused several Anaheim physicians and others of trading on insider information from researchers involved in developing an experimental drug to treat the liver ailment hepatitis B.
BUSINESS
May 6, 1997 | JAMES BATES
TIMES STAFF WRITER What's in a name? For public companies in California, it was Datathis Inc. or Datathat Inc. back in the 1980s, when virtually every garage-based high-tech company was seemingly sprouting into a major publicly held company. In the feel-good '90s, try "For Better Living" or "Excite Inc." There's the bubbly "Affymetrix." And don't forget the friendly "Hello Direct Inc." or helpful "Edify Corp."
BUSINESS
September 25, 1998 | BARBARA MARSH, TIMES STAFF WRITER
In the first federal case involving allegations of insider trading against clinical drug researchers, a federal judge has ordered four Anaheim physicians to pay a total of nearly $350,000 in disgorged profits, avoided losses and penalties. "The lesson to be learned is simple: Medical researchers who trade on this kind of inside information will be found and prosecuted and the penalties will be severe," said Peter H.
BUSINESS
April 27, 1993
California-based firms ranked by dollar amount of offering. Offering Rank Company ($ millions) 1 Foodmaker 180.0 2 Dames & Moore 115.0 3 Pref. Income Opportunity 108.8 4 Ventritex 84.6 5 Gilead Sciences 75.0 6 Providential 67.2 7 North American Mortgage 63.3 8 Pyxis Corporation 56.0 9 Protein Design Labs 52.5 10 Matrix Pharmaceutical 52.5 11 Callaway Golf 52.0 12 PeopleSoft 51.0 13 Trident Microsystems 51.0 14 Cheesecake Factory 46.7 15 Media Vision Technology 45.0 16 Amylin Pharmaceuticals 44.
Los Angeles Times Articles
|